PCSK9 and atherosclerosis: The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER; ClinicalTrials.gov Identifier: NCT01764633) study investigated the potential benefit of treatment with PCSK9 inhibitors to decrease residual risk among subjects with ASCVD and CKD.